
Lonza’s planned facility will be used to develop and manufacture viral gene therapies and virally modified cell therapies

Lonza’s planned facility will be used to develop and manufacture viral gene therapies and virally modified cell therapies

The agency publishes guidance on the physical attributes of generic tablets and capsules.

MFG Tray names ChemTech International as its first Master Pharmaceutical Distributor.

A new SGS Life Science Services laboratory outside Paris is designed for bio/pharmaceutical quality control testing.

Kythera announces that it entered into a definitive agreement to be acquired by Allergan for $2.1 billion.

Careful choice of wash-water parameters and attention to water quality and basket loading are important for optimal cleaning.

Experts at Eppendorf discuss common challenges in cell culture and share insights on possible solutions.

Stan Matthews, sales manager, processing division at MG America, spoke with Pharmaceutical Technology about trends and concerns in capsule production.

The University of Pennsylvania announces that it will collaborate with WuXi AppTech to research and develop gene vectors derived from recombinant viruses.

The Biotechnology Industry Organization announced a name change to the Biotechnology Innovation Organization, effective in early 2016.

Vetter completes on-site expansion activities of visual inspection and in-process control at Chicago facility.

Bayer Healthcare, Bristol-Myers Squibb, Sucampo Pharmaceuticals, Takeda Pharmaceuticals, and Horizon Pharma representatives join PhRMA board.

West Pharmaceutical began construction on its component manufacturing facility located in Waterford, Ireland.

At BIO 2015, CQDM and MaRS Innovation announced an investment in Encycle Therapeutics to research chemical properties needed to make peptide-like molecules orally bioavailable.

The agency creates initiative to stimulate pediatric drug development.

CPhI Worldwide announces five new categories for the 2015 CPhI Pharma Awards.

BPTF seeks changes in performance goals and fee payment schedule in GDUFA renegotiations.

A new GMP facility in Massachusetts will produce enzymes and other reagents for in-vitro diagnostics.

With drug development trends shifting towards personalized medicines, new technologies are needed for the manufacture of these highly sensitive drug products.

An advisory panel deemed Amgen’s Repatha (evolocumab) to be safe overall.

The exclusive manufacturing collaboration will establish production for adeno-associated virus gene-therapy treatments incorporating REGENXBIO’s NAV Technology.

An FDA advisory panel voted 13-3 in favor of approval of Sanofi and Regeneron Pharmaceuticals' cholesterol-homeostasis therapy Praluent (alirocumab).

The supplier will add Allied Laboratories and AR Brown to its list of global partners.

The product, marketed as Sirdupla in the United Kingdom, is the generic version of GSK’s beta agonist and corticosteroid combination treatment for asthma.

The agency issues draft guidance on the development of drugs to treat Duchenne muscular dystrophy.

A year after its merger with DSM Pharmaceutical Products, Patheon announces that it has filed an IPO.

As FDA advisory committees meet on two potential PCSK9 inhibitors, Prime Therapeutics analyzes the impact that this class of drugs may have on overall drug spending.

Lyophilization Services of New England announces inspection approvals that will allow its Bedford, NH facility to begin manufacturing commercial drugs for US distribution.

The MF80 automated punch polisher offers increased polishing capacity per cycle.